ALPI

Intestinal-type alkaline phosphatase · P09923 · ALPI on Sugi Atlas →

63,257 patent compounds predicted against ALPI, 47,135 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL137684	0.78	7/20
Coumaphos (SCHEMBL120173)	0.60	7/20
Haloxon (SCHEMBL167194)	0.57	7/20
SCHEMBL137689	0.67	5/20
SCHEMBL25184	0.63	3/20
SCHEMBL105705	0.49	3/20
Adrenalone (SCHEMBL123124)	0.46	3/20
SCHEMBL31377	0.46	3/20
SCHEMBL127191	0.46	3/20
Isoquercetin (SCHEMBL23249)	1.00	2/20
Isoquercetin (SCHEMBL24609)	1.00	2/20
Isoquercetin (SCHEMBL181306)	1.00	2/20
Avicularin (SCHEMBL119816)	0.98	2/20
Avicularin (SCHEMBL151758)	0.98	2/20
Avicularin (SCHEMBL181203)	0.98	2/20
Quercitrin (SCHEMBL117644)	0.80	2/20
Quercitrin (SCHEMBL147092)	0.80	2/20
Quercitrin (SCHEMBL147093)	0.80	2/20
SCHEMBL24608	0.73	2/20
SCHEMBL180904	0.69	2/20

Clinical trials — most relevant to ALPI by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical Outcome and Future Liver Remnant Regenerative Response in Laparoscopic Versus Open ALPPS	PHASE3	RECRUITING
Pilot Trial of Single Dose Ilofotase Alfa in Hypophosphatasia	PHASE1/PHASE2	COMPLETED
Safety/Efficacy Study of Bovine Intestinal Alkaline Phosphatase in Patients With Moderate to Severe Ulcerative Colitis	PHASE2	COMPLETED
A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis	PHASE2	COMPLETED
Fecal Microbiota Transplantation for Primary Sclerosing Cholangitis - Randomized Study Versus Sham Transplantation	PHASE2	NOT_YET_RECRUITING
Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis	PHASE2	COMPLETED
A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)	PHASE1	RECRUITING
Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid Tumor	PHASE1	COMPLETED
PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers	PHASE1	COMPLETED
Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors	PHASE1	COMPLETED
The Effect of Monoallelic Variants in the ALPL Gene on the Natural Course of Hypophosphatasia in Russia	nan	RECRUITING
Unraveling Genetics of HypoPhosPhatasia (HPP Genetics)	nan	COMPLETED
A Cross-sectional Study on IBS Subtypes, Chinese Medicine Pattern and Host-gut Microbiota Metabolic Interactions	nan	COMPLETED
Registry of Patients With Hypophosphatasia	nan	ENROLLING_BY_INVITATION
Impact of Long-term Serum Magnesium and Potassium Levels Optimization and Multifactorial Adherence Intervention on the Progression of Diabetic Kidney Disease.	nan	UNKNOWN
Natural History Study of Patients With Hypophosphatasia (HPP)	nan	RECRUITING
Characteristics of Hypophosphatasia in Adult Patients in Rheumatology and Their Value in Developing an Algorithm to HPP-diagnosis - the COHIR Multi-center Study	nan	RECRUITING
Serum Alkaline Phosphatase Levels In Healthy Turkish Children	nan	COMPLETED
Characteristics and Predictors of Liver Injury in Cyclin-dependent Kinase Inhibitors 4/6 (CDK4/6)-Treated Patients With Advanced Breast Cancer	nan	COMPLETED
Effect Of Scaling and Root Planning on ALP in Saliva and GCF In Periodontitis Patients Compared With Healthy Individuals	nan	UNKNOWN
A Prospective Sub-Study of the Global Hypophosphatasia Registry	nan	RECRUITING
Evaluation of OMEGAVEN 10%® (n-3 EFA Lipid Emulsion) in Home Parenteral Nutrition-associated Liver Disease	nan	COMPLETED
Characteristics of Hypophosphatasia in Adult Patients in Rheumatology	nan	UNKNOWN
PET/CT Scans Using the Tracer 11C-Csar, a Bile Acid Analog, to Depict and Visualize Changes in the Hepatobiliary System in Patients With Primary Biliary Cholangitis Before and After Treatment.	nan	ACTIVE_NOT_RECRUITING
Exploring the Efficacy and Safety of Herbal Medicine on Korean Obese Women With or Without Metabolic Syndrome Risk Factors - A Study Protocol for a Double-blind, Randomised, Multi-center, Placebo-controlled Clinical Trial	nan	COMPLETED
Liver Function Abnormalities in Patients With Acute Heart Failure	nan	NOT_YET_RECRUITING
Study of Autoimmune Lymphoproliferative Syndrome (ALPS)	nan	RECRUITING
PSC Clinical Epidemiology in China	nan	UNKNOWN
Checkpoint Inhibitor-induced Liver Injury	nan	RECRUITING
Effect of Sugarcane Juice on Liver Patients	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ALPI binder may also engage these)

Protein	Name	Similarity
ALPG	Alkaline phosphatase, germ cell type	0.993	landscape →
ALPL	Alkaline phosphatase, tissue-nonspecific isozyme	0.988	landscape →
P24823	—	0.987	P24823 →
ALPP	Alkaline phosphatase, placental type	0.987	landscape →
Q92058	—	0.986	Q92058 →
P09242	—	0.984	P09242 →
P09487	—	0.982	P09487 →
P19111	—	0.981	P19111 →
P08289	—	0.980	P08289 →
Q29486	—	0.979	Q29486 →
P24822	—	0.978	P24822 →
P15693	—	0.978	P15693 →
Q6UWV6	—	0.959	Q6UWV6 →
P83456	—	0.953	P83456 →
Q3TIW9	—	0.952	Q3TIW9 →
P51740	—	0.951	P51740 →
Q5EZ72	—	0.945	Q5EZ72 →
Q2KHZ8	—	0.942	Q2KHZ8 →
Q32KI9	—	0.940	Q32KI9 →
Q5FYB1	—	0.940	Q5FYB1 →
Q6XPZ3	—	0.940	Q6XPZ3 →
Q70KH2	—	0.940	Q70KH2 →
P17439	—	0.939	P17439 →
Q9BDT0	—	0.939	Q9BDT0 →
GBA1	Lysosomal acid glucosylceramidase	0.938	landscape →
Q5R8E3	—	0.938	Q5R8E3 →
O97583	—	0.938	O97583 →
Q8NCC3	—	0.936	Q8NCC3 →
P58242	—	0.935	P58242 →
Q92485	—	0.934	Q92485 →